| Filed On | Filing |
|---|---|
| 16 Aug 2024 |
8-K: Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more
Section 1. Annual Meetings. The annual meeting of the stockholders of Morphic Holding, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be... |
| 08 Jul 2024 |
8-K: Entry into a Material Definitive Agreement; Other Events
This AGREEMENT AND PLAN OF MERGER, dated as of July 7, 2024 (this “Agreement” and, such date, the “Agreement Date”), is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Rainier Acquisition Corporation, ... |
| 05 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2024, Morphic Holding, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”), at which the matters listed below were submitted to a vote of the Company’s stockholders. There were 47,816,840 s... |
| 26 Apr 2024 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
On April 26, 2024, Morphic Holding, Inc., a Delaware corporation (the “Company” or “Morphic”), entered into a Sales Agreement (the “TD Cowen Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”), under which the Company may offer a... |
| 25 Apr 2024 |
8-K: Results of Operations and Financial Condition
-Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- |
| 12 Mar 2024 |
8-K: Regulation FD Disclosure
Delivering A New Generation Of Integrin Medicines March 2024 |
| 22 Feb 2024 |
8-K: Results of Operations and Financial Condition
-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)- |
| 12 Jan 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Delivering A New Generation Of Integrin Medicines January 2024 |
| 03 Jan 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
-Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- |
| 06 Dec 2023 |
8-K: Amendments to or Waivers of the Code of Ethics
Morphic Holding, Inc., a Delaware corporation (collectively with its subsidiaries, the “Company”) has adopted this Code of Conduct and Ethics (this “Code”) to set high standards of ethical business conduct and provide guidance applicable... |
| 03 Nov 2023 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- |
| 12 Oct 2023 |
8-K: Results of Operations and Financial Condition; Other Events
This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the timing and success... |
| 26 Sep 2023 |
8-K: Departure/Election of Directors or Officers; Compensation
WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) – Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence. Dr. Ti... |
| 03 Aug 2023 |
8-K: Results of Operations and Financial Condition
-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- |
| 02 Jun 2023 |
8-K: Submission of Matters to a Vote of Security Holders
On June 1, 2023, Morphic Holding, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), at which the matters listed below were submitted to a vote of the Company’s stockholders. There were 38,438,654 s... |
| 03 May 2023 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. Morphic Holding, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 5,333,334 shares of its common stock, par value ... |
| 25 Apr 2023 |
8-K: Other Events
Forward Looking Statements This presentation contains “forward - looking” statements within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995, including, but not limited to statements re... |
| 25 Apr 2023 |
8-K: Results of Operations and Financial Condition; Other Events
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no safety signal observed - |
| 23 Feb 2023 |
8-K: Results of Operations and Financial Condition
-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- |
| 13 Feb 2023 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2023 by and among Morphic Holding, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto ... |
Loading...